Maine House Bill LD2011

Maine 2025-2026 Regular Session

• Introduced: 12/3/25
• Refer: 12/3/25
• Engrossed: 2/24/26
• Enrolled: 3/3/26
• Passed: 3/10/26

Caption

An Act to Remove the MaineCare Program from the Prescription Drug Benefit Provisions in the Maine Insurance Code

Summary

LD 2011 amends Maine’s insurance code definition of “carrier” in the prescription drug benefit provisions. Under current law, the definition expressly includes the MaineCare program and the state employee health plan; this bill removes MaineCare from that definition while leaving the state employee plan and other covered entities in place. The measure is narrowly drafted and does not create a new benefit program or change prescription drug coverage standards generally; instead, it changes which public programs are treated as a “carrier” for purposes of the cited insurance code provisions. In practical terms, the bill shifts MaineCare out of the prescription drug benefit provisions in Title 24-A, chapter 43, section 4347, which may affect how those insurance-code requirements apply to MaineCare administration and oversight. The bill leaves intact the broader MaineCare program under Title 22, chapter 855, but removes its explicit inclusion in this insurance-code section, likely reducing overlap between Medicaid administration and private insurance regulatory language. The bill was enacted as Public Law 2025, chapter 561. The available voting history suggests the bill was generally supported, with the House adopting an “Ought to Pass” report by a wide margin of 106-23. No committee transcript excerpts were provided, so there is no recorded debate text here to indicate detailed arguments for or against the measure. The final enactment indicates the bill moved through the Legislature successfully and was signed by the Governor. Because the bill is technical and targeted, the main point of contention appears to be whether MaineCare should remain subject to insurance-code prescription drug benefit provisions at all. Supporters likely viewed the change as a clarification or cleanup to separate Medicaid from private insurance rules, while opponents may have been concerned about any reduction in statutory protections or oversight tied to prescription drug benefits. The vote margin suggests limited but present opposition, likely centered on the policy implications of carving MaineCare out of the definition of carrier.

Impact

The bill amends 24-A MRSA §4347, subsection 3 to remove the MaineCare program from the insurance code’s prescription drug benefit provisions by narrowing the statutory definition of “carrier.” MaineCare remains governed by Title 22, chapter 855, but it is no longer expressly included in this specific insurance-code section. The change affects how prescription drug benefit rules in the Maine Insurance Code apply to MaineCare and may reduce cross-application of private insurance terminology and requirements to the Medicaid program.

Sentiment

The overall sentiment appears favorable and largely noncontroversial, as reflected by the strong House vote of 106-23 for an “Ought to Pass” report and the bill’s eventual enactment. The absence of committee transcript material limits insight into detailed debate, but the final outcome suggests broad agreement that the bill was a technical correction or clarification. The recorded opposition indicates some concern remained, but not enough to prevent passage.

Contention

The main point of contention is the policy choice to exclude MaineCare from the prescription drug benefit provisions in the Maine Insurance Code. Supporters likely argued that MaineCare should be governed under its own Medicaid statutes rather than insurance-code carrier rules, while critics may have worried that removing MaineCare from the definition of “carrier” could weaken consistency, oversight, or protections related to prescription drug benefits. The vote count shows some resistance, but no detailed committee record is available to identify specific legislators or stakeholder groups raising objections.